GMED
Globus Medical, Inc. · Healthcare · Medical - Devices
Momentum inputs (comparable managers):
holder breadth -9.5% ·
share flow +2.1% ·
net new positions -10.5%
· formula
Concentrated accumulation: rising shares among fewer holders
All ownership figures: tracked 13F managers only, common-stock positions, reporting period Q2 2025
| Quarter | Holders | Δ | Shares | Reported value | New | Exits |
|---|---|---|---|---|---|---|
| Q3 2026 | 4 | 0 | 80.59K | $4.78M | n/a | n/a |
| Q2 2026 | 123 | -3 | 71.27M | $5.66B | +7 | −9 |
| Q1 2026 | 128 | +3 | 69.73M | $6.00B | +7 | −5 |
| Q4 2025 | 125 | -2 | 72.17M | $6.30B | +1 | −2 |
| Q3 2025 | 23 | +2 | 41.89M | $2.40B | +2 | −1 |
| Q2 2025 | 19 | -2 | 35.55M | $2.10B | n/a | −2 |
| Q1 2025 | 18 | +2 | 12.57M | $919.97M | +3 | −1 |
| Q4 2024 | 16 | 0 | 17.69M | $1.46B | +1 | −1 |
| Q3 2024 | 15 | 0 | 11.77M | $842.11M | +1 | −1 |
| Q2 2024 | 15 | n/a | 12.93M | $885.43M | n/a | n/a |
| # | Manager | Shares | Δ shares | Value | Their weight | Held | ||
|---|---|---|---|---|---|---|---|---|
| 1 | BlackRock ✦ (passive) | 10.76M | n/a | $635.26M | 0.0% | n/c | 1 | SEC ↗ ×18 |
| 2 | The Vanguard Group ✦ (passive) | 10.71M | n/a | $632.04M | 0.0% | n/c | 1 | SEC ↗ ×5 |
| 3 | State Street Global Advisors ✦ (passive) | 3.47M | -3.9% | $205.00M | 0.0% | ▼ Trim | 3 | SEC ↗ |
| 4 | Geode Capital Management ✦ (passive) | 1.99M | -1.9% | $117.67M | 0.0% | ▼ Trim | 5 | SEC ↗ ×2 |
| 5 | Wellington Management ✦ | 1.97M | +4.6% | $116.19M | 0.0% | ▲ Add | 5 | SEC ↗ ×4 |
| 6 | Marshall Wace ✦ | 1.58M | +89.7% | $93.28M | 0.1% | ▲ Add | 5 | SEC ↗ ×3 |
| 7 | Norges Bank ✦ (passive) | 1.15M | +2.5% | $68.04M | 0.0% | ▲ Add | 5 | SEC ↗ |
| 8 | T. Rowe Price ✦ | 1.07M | -6.4% | $63.43M | 0.0% | ▼ Trim | 5 | SEC ↗ ×2 |
| 9 | Fidelity (FMR) ✦ | 760.38K | n/a | $44.88M | 0.0% | n/c | 1 | SEC ↗ ×4 |
| 10 | Capital World Investors ✦ | 574.50K | 0.0% | $33.91M | 0.0% | Held | 5 | SEC ↗ |
| 11 | Bridgewater Associates ✦ | 436.64K | +228.0% | $25.77M | 0.1% | ▲ Add | 2 | SEC ↗ |
| 12 | Fisher Asset Management ✦ | 288.07K | -12.9% | $17.00M | 0.0% | ▼ Trim | 5 | SEC ↗ |
| 13 | Gotham Asset Management ✦ | 244.08K | +91.0% | $14.41M | 0.1% | ▲ Add | 3 | SEC ↗ |
| 14 | GAMCO Investors ✦ | 135.29K | +1.1% | $7.98M | 0.1% | ▲ Add | 5 | SEC ↗ |
| 15 | AQR Capital Management ✦ | 112.00K | +397.6% | $6.59M | 0.0% | ▲ Add | 5 | SEC ↗ ×4 |
| 16 | Renaissance Technologies ✦ | 105.42K | -40.4% | $6.22M | 0.0% | ▼ Trim | 2 | SEC ↗ |
| 17 | Arrowstreet Capital ✦ | 103.47K | +34.3% | $6.11M | 0.0% | ▲ Add | 2 | SEC ↗ |
| 18 | PRIMECAP Management ✦ | 35.62K | -7.5% | $2.10M | 0.0% | ▼ Trim | 5 | SEC ↗ |
| 19 | Millennium Management ✦ | 34.23K | +150.8% | $2.02M | 0.0% | ▲ Add | 5 | SEC ↗ |
“Their weight” = the position's share of that manager's reported 13F equity value: the conviction measure. ✦ = curated manager.
New buyers
| No new tracked buyers this quarter. |
Exited
| Citadel Advisors | $20.89M | was 0.0% |
| Two Sigma Investments | $1.23M | was 0.0% |
Full-market context: across ALL 13F filers (SEC structured data, Q1 2026): 598 holders, 106.58M shares, $8.83B reported. This is a different, older period than the tracked-universe figures above and the two are never mixed.
What else this security's tracked holders most often hold: shared-ownership counts, not fundamental relationships.
Open-market purchases (P)
No open-market insider purchases in our coverage window.
Open-market sales (S)
Director · 30.00K sh · $2.24M
Director · 25.00K sh · $2.18M
Awards, exercises and tax withholding are never counted as buys or sales here. Methodology